IPSEN (OTCMKTS:IPSEY) Stock Price Up 7.5% – Still a Buy?

IPSEN (OTCMKTS:IPSEY)’s share price was up 7.5% on Friday . The company traded as high as $48.1850 and last traded at $48.1850. Approximately 169 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 2,113 shares. The stock had previously closed at $44.81.

Analyst Ratings Changes

Several research firms have recently issued reports on IPSEY. Zacks Research raised IPSEN to a “hold” rating in a research report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Finally, HC Wainwright restated a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, IPSEN has an average rating of “Hold”.

IPSEN Stock Performance

The company’s 50 day moving average is $45.87 and its 200 day moving average is $45.50.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).